Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01828099
Recruitment Status : Active, not recruiting
First Posted : April 10, 2013
Results First Posted : September 21, 2017
Last Update Posted : March 14, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The primary purpose of the study was to compare the antitumor activity of LDK378 versus reference chemotherapy. Patients in the chemotherapy arm were allowed to cross-over to LDK378 after confirmed progressive disease (PD).

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: Ceritinib Drug: Pemetrexed Drug: Cisplatin Drug: Carboplatin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 375 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer
Actual Study Start Date : March 13, 2013
Actual Primary Completion Date : June 24, 2016
Estimated Study Completion Date : April 11, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Ceritinib

Arm Intervention/treatment
Experimental: Ceritinib
Ceritinib patients were on continuous oral dosing of ceritinib 750 mg once daily in fasted state.
Drug: Ceritinib
Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule. Ceritinib (LDK378) was the investigational treatment and is referred to as the investigational study treatment/drug.
Other Name: LDK378

Active Comparator: Chemotherapy
Chemotherapy patients (Induction per Investigator's choice) were on four 21-day cycles of Pemetrexed 500mg/m2 iv + Cisplatin 75 mg/m2 or Pemetrexed 500 mg/m2 iv + Carboplatin AUC 5-6 iv followed by Pemetrexed 500 mg/m2 every 21 days followed by Pemetrexed maintenance in non-progressors, etc (other usual rule to stop treatment).
Drug: Pemetrexed
Pemetrexed was administered at a dose of 500 mg/m2 as an iv infusion on Day 1 of each 21-day cycle to patients randomized to the chemotherapy arm.

Drug: Cisplatin
Cisplatin was administered by IV at a dose of 75 mg/m2 every 21 days for up to 4 cycles.

Drug: Carboplatin
Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles




Primary Outcome Measures :
  1. Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) [ Time Frame: from the date of randomization to the date of first radiologically documented disease progression or death due to any cause (assessed every 6 weeks up to approximately 34 months) ]
    PFS defined as time from date of randomization to date of first documented disease (as assessed by Blinded Independent Review Committee (BIRC) per RECIST 1.1) or date of death due to any cause


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: From randomization until death (up to approximately 34 months) ]
    OS defined as time from date of randomization to date of death due to any cause

  2. Overall Response Rate (ORR) [ Time Frame: From randomization until death (up to approximately 34 months) ]
    ORR defined as the proportion of patients with a best overall response defined as Complete Response (CR) or Partial Response (PR) as evaluated by Blinded Independent Review Committee (BIRC) and by investigator assessment per RECIST 1.1

  3. Duration of Response (DOR) [ Time Frame: From randomization until death (up to approximately 34 months) ]
    DOR defined as the time from date of first documented CR or PR to date of first documented disease progression or death due to any cause

  4. Disease Control Rate (DCR) [ Time Frame: From randomization until death (up to approximately 34 months) ]
    DCR defined as the proportion of patients with best overall response of CR, PR, or Stable Disease (SD)

  5. Time to Response (TTR) [ Time Frame: From randomization until death (up to approximately 34 months) ]
    TTR defined as the time from date of randomization to date of first documented response (CR or PR)

  6. Patient Reported Outcomes [ Time Frame: Screening, followed by every 6 weeks until Month 33 after Month 33 every 9 weeks. ]
    The time to definitive deterioration from the date of randomization to the date of event for disease related symptoms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient has a histologically or cytologically confirmed diagnosis of non-squamous Non-small cell lung cancer (NSCLC) that is Anaplastic lymphoma kinase (ALK) positive as assessed by the Ventana Immunohistochemistry (IHC) test. The test will be performed at Novartis designated central laboratories.
  2. Patient has newly diagnosed stage IIIB (who are not a candidate for definitive multimodality therapy) or stage IV NSCLC or relapsed locally advanced or metastatic NSCLC not previously treated with any systemic anti-cancer therapy (e.g. cytotoxic drugs, monoclonal antibody therapy, crizotinib or other ALK inhibitors, or other targeted therapies, either experimental or not), with exception of neo-adjuvant or adjuvant therapy
  3. Patient has at least one measurable lesion as defined by RECIST 1.1.

Exclusion Criteria:

  1. Patient with known hypersensitivity to any of the excipients of LDK378 (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)
  2. Patient with a history of severe hypersensitivity reaction to platinum containing drugs, pemetrexed or any known excipients of these drugs.
  3. Patient with symptomatic central nervous system (CNS) metastases who is neurologically unstable or has required increasing doses of steroids within the 2 weeks prior to screening to manage CNS symptoms.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01828099


  Hide Study Locations
Locations
Layout table for location information
Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1050AAK
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1180AAX
Novartis Investigative Site
La Rioja, Argentina, 5300
Australia, Queensland
Novartis Investigative Site
Woolloongabba, Queensland, Australia, 4102
Australia, Victoria
Novartis Investigative Site
Heidelberg, Victoria, Australia, 3084
Australia
Novartis Investigative Site
Auckland, Australia, 92024
Austria
Novartis Investigative Site
Salzburg, Austria, 5020
Novartis Investigative Site
Wien, Austria, A-1140
Brazil
Novartis Investigative Site
Salvador, BA, Brazil, 40170-110
Novartis Investigative Site
Fortaleza, CE, Brazil, 60336-045
Novartis Investigative Site
Recife, PE, Brazil, 50070-550
Novartis Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90610-000
Novartis Investigative Site
Rio De Janiero, RJ, Brazil, 20231-050
Novartis Investigative Site
Natal, RN, Brazil, 59075 740
Novartis Investigative Site
Itajai, SC, Brazil, 88301-229
Novartis Investigative Site
Barretos, SP, Brazil, 14784 400
Novartis Investigative Site
Sao Jose do Rio Preto, SP, Brazil, 15090 000
Novartis Investigative Site
São Paulo, SP, Brazil, 01246-000
China, Beijing
Novartis Investigative Site
Beijing, Beijing, China, 100730
China, Chongqing
Novartis Investigative Site
Chongqing, Chongqing, China, 400037
China, Guangdong
Novartis Investigative Site
Guangzhou, Guangdong, China, 51000
China, Jilin
Novartis Investigative Site
Chang Chun, Jilin, China, 130021
Novartis Investigative Site
Changchun, Jilin, China, 130012
China, Shanghai
Novartis Investigative Site
Shanghai, Shanghai, China, 200433
China, Shanxi
Novartis Investigative Site
Xi'an, Shanxi, China, 710038
China, Sichuan
Novartis Investigative Site
Chengdu, Sichuan, China, 610041
China, Zhejiang
Novartis Investigative Site
Hangzhou, Zhejiang, China, 310003
Novartis Investigative Site
Hangzhou, Zhejiang, China, 310022
China
Novartis Investigative Site
Beijing, China, 101149
Novartis Investigative Site
Chongqing, China, 400042
Novartis Investigative Site
Guang Dong Province, China, 510120
Novartis Investigative Site
Tianjin, China, 300052
Colombia
Novartis Investigative Site
Bogota, Cundinamarca, Colombia, 110111
Novartis Investigative Site
Monteria, Colombia
Denmark
Novartis Investigative Site
Herlev, Denmark, DK-2730
Novartis Investigative Site
Odense C, Denmark, DK-5000
France
Novartis Investigative Site
Toulon Cedex 9, Val De Marne, France, 83800
Novartis Investigative Site
Caen, France, 14033
Novartis Investigative Site
Grenoble, France, 38043
Novartis Investigative Site
LILLE Cédex, France, 59037
Novartis Investigative Site
Limoges Cedex, France, 87042
Novartis Investigative Site
Paris, France, 75010
Novartis Investigative Site
Pierre Benite, France, 69495
Novartis Investigative Site
Rennes, France, 35043
Novartis Investigative Site
Strasbourg Cedex, France, 67091
Novartis Investigative Site
Villejuif Cedex, France, 94805
Germany
Novartis Investigative Site
Koeln, Nordrhein-Westfalen, Germany, 50937
Novartis Investigative Site
Coswig, Germany, 01640
Novartis Investigative Site
Essen, Germany, 45147
Novartis Investigative Site
Goettingen, Germany, 37075
Novartis Investigative Site
Grosshansdorf, Germany, 22947
Novartis Investigative Site
Heidelberg, Germany, 69120
Novartis Investigative Site
Oldenburg, Germany, 26121
Novartis Investigative Site
Tuebingen, Germany, 72076
Novartis Investigative Site
Ulm, Germany, 89081
Novartis Investigative Site
Wiesbaden, Germany, D-65199
Greece
Novartis Investigative Site
Athens, GR, Greece, 115 27
Novartis Investigative Site
Heraklion Crete, Greece, 711 10
Hungary
Novartis Investigative Site
Budapest, Hungary, 1121
Novartis Investigative Site
Nyiregyhaza, Hungary, 4400
Novartis Investigative Site
Veszprem, Hungary, 8200
Novartis Investigative Site
Zalaegerszeg-Pózva, Hungary, 8900
India
Novartis Investigative Site
Hyderabad, Andhra Pradesh, India, 500 034
Novartis Investigative Site
New Delhi, Delhi, India, 110076
Novartis Investigative Site
Bangalore, Karnataka, India, 560 095
Novartis Investigative Site
Kochi, Kerala, India, 682 041
Novartis Investigative Site
Nashik, Maharashtra, India, 422 004
Novartis Investigative Site
Jaipur, Rajasthan, India, 302017
Novartis Investigative Site
Madurai, Tamil NADU, India, 625107
Novartis Investigative Site
Vellore, Tamil Nadu, India, 632 004
Novartis Investigative Site
Kolkata, West Bengal, India, 700160
Novartis Investigative Site
Delhi, India, 110 085
Novartis Investigative Site
Mumbai, India, 400 012
Ireland
Novartis Investigative Site
Limerick, Co Limerick, Ireland
Novartis Investigative Site
Dublin 4, Ireland
Italy
Novartis Investigative Site
Bergamo, (bg), Italy, 24125
Novartis Investigative Site
Ancona, AN, Italy, 60126
Novartis Investigative Site
Cremona, CR, Italy, 26100
Novartis Investigative Site
Catanzaro, CZ, Italy, 88100
Novartis Investigative Site
Genova, GE, Italy, 16132
Novartis Investigative Site
Monza, MB, Italy, 20900
Novartis Investigative Site
Milano, MI, Italy, 20132
Novartis Investigative Site
Milano, MI, Italy, 20141
Novartis Investigative Site
Milano, MI, Italy, 20162
Novartis Investigative Site
Rozzano, MI, Italy, 20089
Novartis Investigative Site
Perugia, PG, Italy, 06129
Novartis Investigative Site
Pisa, PI, Italy, 56124
Novartis Investigative Site
Aviano, PN, Italy, 33081
Novartis Investigative Site
Parma, PR, Italy, 43100
Novartis Investigative Site
Reggio Emilia, RE, Italy, 42123
Novartis Investigative Site
Roma, RM, Italy, 00152
Novartis Investigative Site
Roma, RM, Italy, 00189
Novartis Investigative Site
Taranto, TA, Italy, 74100
Novartis Investigative Site
Orbassano, TO, Italy, 10043
Novartis Investigative Site
Udine, UD, Italy, 33100
Novartis Investigative Site
Napoli, Italy, 80131
Japan
Novartis Investigative Site
Nagoya, Aichi, Japan, 464 8681
Novartis Investigative Site
Kashiwa, Chiba, Japan, 277 8577
Novartis Investigative Site
Akashi, Hyogo, Japan, 673-8558
Novartis Investigative Site
Hirakata-city, Osaka, Japan, 573-1191
Novartis Investigative Site
Osaka-city, Osaka, Japan, 541-8567
Novartis Investigative Site
Sayama, Osaka, Japan, 589 8511
Novartis Investigative Site
Koto ku, Tokyo, Japan, 135 8550
Novartis Investigative Site
Niigata, Japan, 951 8520
Korea, Republic of
Novartis Investigative Site
Bundang-gu, Gyeonggi Do, Korea, Republic of, 13620
Novartis Investigative Site
Gyeonggi do, Korea, Korea, Republic of, 10408
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 05505
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 06351
Novartis Investigative Site
Seoul, Korea, Republic of, 03722
Lebanon
Novartis Investigative Site
Ashrafieh, Lebanon, 166830
Novartis Investigative Site
Saida, Lebanon, 652
Mexico
Novartis Investigative Site
Guadalajara, Jalisco, Mexico, 44280
Netherlands
Novartis Investigative Site
Maastricht, AZ, Netherlands, 5800
Novartis Investigative Site
Amsterdam, Netherlands, 1066 CX
Novartis Investigative Site
Amsterdam, Netherlands, 1081 HV
Novartis Investigative Site
Breda, Netherlands, 4819 EV
Novartis Investigative Site
Enschede, Netherlands, 7513 ER
Novartis Investigative Site
Groningen, Netherlands, 9713 GZ
Novartis Investigative Site
Groningen, Netherlands, 9728 NT
Novartis Investigative Site
Harderwijk, Netherlands, 3840 AC
Novartis Investigative Site
Hertogenbosch, Netherlands, 5200
Novartis Investigative Site
Leiden, Netherlands, 2300 RC
Novartis Investigative Site
Zwolle, Netherlands, 8025 AB
Norway
Novartis Investigative Site
Oslo, Norway, NO-0424
Poland
Novartis Investigative Site
Gdansk, Poland, 80 952
Novartis Investigative Site
Konin, Poland, 62 500
Novartis Investigative Site
Szczecin, Poland, 70-891
Novartis Investigative Site
Warszawa, Poland, 02 781
Portugal
Novartis Investigative Site
Porto, Portugal, 4099-001
Russian Federation
Novartis Investigative Site
Moscow, Russian Federation, 115478
Novartis Investigative Site
Saint Petersburg, Russian Federation, 197022
Singapore
Novartis Investigative Site
Singapore, Singapore, 119228
Novartis Investigative Site
Singapore, Singapore, 169610
Spain
Novartis Investigative Site
Granada, Andalucia, Spain, 18014
Novartis Investigative Site
Malaga, Andalucia, Spain, 29010
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41013
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41014
Novartis Investigative Site
Oviedo, Asturias, Spain, 33006
Novartis Investigative Site
Lleida, Cataluna, Spain, 25198
Novartis Investigative Site
Mataro, Cataluna, Spain, 08301
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08003
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Hospitalet de LLobregat, Catalunya, Spain, 08907
Novartis Investigative Site
Alicante, Comunidad Valenciana, Spain, 03010
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46014
Novartis Investigative Site
Badajoz, Extremadura, Spain, 06080
Novartis Investigative Site
La Coruna, Galicia, Spain, 15006
Novartis Investigative Site
Lugo, Galicia, Spain, 27003
Novartis Investigative Site
Palma De Mallorca, Islas Baleares, Spain, 07120
Novartis Investigative Site
Pamplona, Navarra, Spain, 31008
Novartis Investigative Site
La Laguna, Santa Cruz De Tenerife, Spain, 38320
Novartis Investigative Site
Reus, Tarragona, Spain, 43201
Novartis Investigative Site
Barcelona, Spain, 08041
Novartis Investigative Site
Madrid, Spain, 28033
Novartis Investigative Site
Madrid, Spain, 28040
Novartis Investigative Site
Madrid, Spain, 28041
Novartis Investigative Site
Madrid, Spain, 28050
Sweden
Novartis Investigative Site
Eskilstuna, Sweden, SE-631 88
Novartis Investigative Site
Linköping, Sweden, SE-581 85
Novartis Investigative Site
Lund, Sweden, SE-221 85
Novartis Investigative Site
Stockholm, Sweden, 171 76
Novartis Investigative Site
Uppsala, Sweden, 751 85
Taiwan
Novartis Investigative Site
Tainan, Taiwan ROC, Taiwan, 70421
Novartis Investigative Site
Taipei, Taiwan, ROC, Taiwan, 11217
Novartis Investigative Site
Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan, 33305
Novartis Investigative Site
Kaohsiung City, Taiwan, 83301
Novartis Investigative Site
Taichung City, Taiwan, 407
Novartis Investigative Site
Taichung, Taiwan, 40447
Novartis Investigative Site
Taipei, Taiwan, 10048
Thailand
Novartis Investigative Site
Songkla, Hat Yai, Thailand, 90110
Novartis Investigative Site
Khon Kaen, THA, Thailand, 40002
Novartis Investigative Site
Bangkok, Thailand, 10210
Novartis Investigative Site
Bangkok, Thailand, 10330
Novartis Investigative Site
Bangkok, Thailand, 10400
Turkey
Novartis Investigative Site
Ankara, Sihhiye, Turkey, 06100
Novartis Investigative Site
Istanbul, Turkey, 34303
Novartis Investigative Site
Izmir, Turkey, 35040
United Kingdom
Novartis Investigative Site
Leeds, West Yorkshire, United Kingdom, LS9 7TF
Novartis Investigative Site
Birmingham, United Kingdom, B9 5SS
Novartis Investigative Site
Exeter, United Kingdom, EX2 5DW
Novartis Investigative Site
London, United Kingdom, NW1 2PJ
Novartis Investigative Site
Manchester, United Kingdom, M20 2BX
Novartis Investigative Site
Nottingham, United Kingdom, NG5 1PB
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01828099     History of Changes
Other Study ID Numbers: CLDK378A2301
2013-000319-26 ( EudraCT Number )
First Posted: April 10, 2013    Key Record Dates
Results First Posted: September 21, 2017
Last Update Posted: March 14, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Non-Small Cell Lung Cancer
treatment of lung cancer after first metastasis
lung cancer
Non small cell lung cancer
non-squamous non-small cell lung cancer
NSCLC
ALK
LDK378
Non-small cell lung carcinoma (NSCLC)
lung adenocarcinoma
Non small cell lung carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Bronchial Neoplasms
Carcinoma, Non-Small-Cell Lung
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Cisplatin
Carboplatin
Pemetrexed
Ceritinib
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors
Protein Kinase Inhibitors